Pacira BioSciences and the Class Action Lawsuit
The Gross Law Firm has issued important information for shareholders of Pacira BioSciences, Inc. (NASDAQ: PCRX). Recently, the firm has filed a class action lawsuit, which highlights serious allegations concerning the company. The lawsuit has significant implications for investors who acquired shares during the specified class period.
What the Lawsuit Entails
The class action refers to the period during which investors bought shares of Pacira BioSciences. The allegations center around a legal battle over a patent related to Exparel, a product that has been a cornerstone of the company's revenue. On August 9, significant news broke when the court declared that Pacira's U.S. Patent No. 11,033,495 was invalid. This ruling raised concerns about the future of Exparel and its market position, as it opened doors for potential generic competitors.
Impact on Stock Performance
Following the announcement regarding the patent ruling, Pacira's shares plummeted. The stock experienced a staggering drop, falling over 47% in one day. Investors were left reeling as the shares, which closed at $22.36 on August 8, dropped to a low of $11.70 the next day. This sharp decline has put pressure on the company and raised alarms among its shareholders.
Details of the Class Period
The class period for the current lawsuit spans from August 2, 2023, to August 8, 2024. The Gross Law Firm urges all shareholders who purchased shares during this time to make their voices heard. Notably, being appointed as a lead plaintiff is not a prerequisite for any recovery.
Next Steps for Shareholders
Shareholders are encouraged to register their information promptly to participate in this class action. This registration provides access to ongoing updates about the case and helps keep shareholders informed. The deadline for registering to seek lead plaintiff status is March 14. It's important to note that there are no fees or obligations to participate in this legal action.
Why Choose The Gross Law Firm?
The Gross Law Firm has built a reputation as a recognized advocate for investors. Their mission is to uphold the rights of those impacted by misleading corporate actions. The firm focuses on holding companies accountable for their business practices. When investors face losses due to potentially deceptive behavior, The Gross Law Firm strives to ensure they receive the justice they deserve.
Company Contact Information
For more details, interested shareholders can get in touch with The Gross Law Firm. Here are the contact details for inquiries:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY 10018
Phone: (646) 453-8903
Frequently Asked Questions
What is the primary focus of the class action lawsuit?
The class action lawsuit primarily focuses on allegations relating to the invalidation of a patent critical to Pacira's main revenue source, Exparel.
How will this lawsuit affect shareholders?
Shareholders who registered may be eligible for recovery if the lawsuit results in a favorable outcome.
What can shareholders do to protect their rights?
Shareholders should register with The Gross Law Firm to stay updated on the case and to be considered for lead plaintiff status.
Is there a cost to participate in the class action?
No, there are no costs or obligations for shareholders to participate in this case.
When is the registration deadline?
The deadline for shareholders to register is March 14, 2025, making it crucial to act promptly.
